Peanut Allergy Treatment Available in the USA

Aimmune Therapeutics PALFORZIA is approved for peanut allergy treatment in the USA
peanuts in a serving dish
(Precision Vaccinations)

A Californa based biopharmaceutical company announced that the initial patients are being treated with PALFORZIA, the first approved treatment for peanut allergy in the USA.

PALFORZIA is approved for use in patients with a confirmed diagnosis of peanut allergy and in conjunction with a peanut-avoidant diet.

Peanut allergy is a condition in which the body’s immune system mistakenly identifies even small amounts of peanut as harmful.

A 2017 study reported that peanut allergy in children had increased 21 percent since 2010 and that nearly 2.5 percent of U.S. children may have an allergy to peanuts.

According to Aimmune Therapeutic on March 16, 2020, specialty pharmacies are shipping PALFORZIA dosing kits to allergists for in-office administration to certain peanut-allergic patients with a confirmed diagnosis of peanut allergy.

“We are pleased that peanut-allergic children are being treated with PALFORZIA just 6-weeks after its FDA approval,” said Jayson Dallas, M.D., President and CEO of Aimmune, in a press release. 

“Since our REMS website went live, well over 600 allergists are now certified and ready to prescribe PALFORZIA to their patients.”

PALFORZIA may only be administered to patients by allergists and allergy practices that have been certified under the Risk Evaluation and Mitigation Strategy program. 

PALFORZIA was approved by the U.S. Food and Drug Administration on January 31, 2020, as oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanut.

Initial dose escalation may be administered to patients aged 4 through 17 years. Up-dosing and maintenance may be continued in patients 4 years of age and older. 

PALFORZIA is to be used in conjunction with a peanut-avoidant diet. PALFORZIA is not indicated for the emergency treatment of allergic reactions, including anaphylaxis.

Dispensing of PALFORZIA is limited to contracted pharmacies that will be certified in the PALFORZIA REMS Program. A list of certified allergists who are able to provide PALFORZIA treatment may be viewed here. 

Aimmune Therapeutics, Inc. is a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies.

Peanut allergy treatment news published by Precision Vaccinations.